(Q53417132)

14 May 2018

title

p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases. (English)

1 reference

14 May 2018

author name string

Marrogi AJ

1

1 reference

14 May 2018

Khan MA

2

1 reference

14 May 2018

Vonderheid EC

3

1 reference

14 May 2018

Wood GS

4

1 reference

14 May 2018

McBurney E

5

1 reference

14 May 2018

publication date

1 September 1999

1 reference

14 May 2018

Journal of Cutaneous Pathology

published in

1 reference

14 May 2018

volume

26

1 reference

14 May 2018

issue

8

1 reference

14 May 2018

page(s)

369-378

1 reference

14 May 2018

Localization of human T-cell lymphotropic virus-1 tax proviral sequences in skin biopsies of patients with mycosis fungoides by in situ polymerase chain reaction

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

The p53 proto-oncogene can act as a suppressor of transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Mycosis fungoides: expression of C-myc p62 p53, bcl-2 and PCNA proteins and absence of association with Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Analysis of p53 and mdm-2 expression in 18 patients with Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

p53 oncoprotein expression in cutaneous lymphoproliferations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

p53 and c-erbB-2 protein expression in adenocarcinomas and epithelial dysplasias of the gall bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Clinical implications of the p53 tumor-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

p53 is required for radiation-induced apoptosis in mouse thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

p53 function and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

Therapeutic targeting of the p53 tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0560.1999.TB01860.X

10.1111/J.1600-0560.1999.TB01860.X

21 January 2018

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018